Covestor’s TG Therapeutics TGTX Stock Holding History

Covestor’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$84K	Sell	1,503 -755	-33%	-$40.9K	0.05%	445
2026 Q2	$124K	Sell	2,258 -123	-5%	-$5.03K	0.07%	265
2026 Q1	$79K	Buy	2,381 +571	+32%	+$17K	0.05%	404
2025 Q4	$54K	Buy	1,810 +1,537	+563%	+$50.2K	0.03%	883
2025 Q3	$10K	Hold	273	–	–	0.01%	1616
2025 Q2	$10K	Buy	273 +265	+3,313%	+$9.9K	0.01%	1611
2025 Q1	$0	Hold	8	–	–	﹤0.01%	2721
2024 Q4	$0	Hold	8	–	–	﹤0.01%	2735
2024 Q3	$0	Sell	8 -3	-27%	-$66	﹤0.01%	2760
2024 Q2	$0	Hold	11	–	–	﹤0.01%	2748
2024 Q1	$0	Sell	11 -4	-27%	-$64	﹤0.01%	2730
2023 Q4	$0	Buy	15 +7	+88%	+$81	﹤0.01%	2707
2023 Q3	$0	Sell	8 -1	-11%	-$14	﹤0.01%	2704
2023 Q2	$0	Sell	9 -3	-25%	-$77	﹤0.01%	2642
2023 Q1	$0	Buy	+12	New	+$182	﹤0.01%	2581
2022 Q1	–	Sell	-3	Closed	–	–	2442
2021 Q4	$0	Buy	+3	New	+$78	﹤0.01%	2299

Other funds holding TGTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Covestor's TGTX Position: Q3 2026 in Review

Covestor reduced its TG Therapeutics (TGTX) stake by 33% in Q3 2026, selling an estimated $40.9K and leaving 1,503 shares worth $84K. The position accounts for 0.05% of the portfolio, ranked #445.

Covestor first reported a position in TGTX in Q4 2021 and has held it in 16 quarters since. The position peaked at $124K in Q2 2026. 197 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

Covestor held 1,503 shares of TG Therapeutics worth $84K as of Q3 2026.
Covestor sold 755 TG Therapeutics shares in Q3 2026, an estimated $40.9K.
TG Therapeutics made up 0.05% of Covestor's portfolio in Q3 2026, its #445 holding.
Covestor first reported a position in TG Therapeutics in Q4 2021 and has held it in 16 quarters since.
Covestor's TG Therapeutics position peaked at $124K in Q2 2026.
197 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.